A5011472777- Genetic Associations and Epidemiology
- Lipoproteins and Cardiovascular Health
- Pharmacogenetics and Drug Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lipid metabolism and disorders
- Drug Transport and Resistance Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Peroxisome Proliferator-Activated Receptors
- Adipokines, Inflammation, and Metabolic Diseases
- Liver Disease Diagnosis and Treatment
- Cholesterol and Lipid Metabolism
- Gout, Hyperuricemia, Uric Acid
- Diet and metabolism studies
- Nutrition, Genetics, and Disease
- Gut microbiota and health
- Adipose Tissue and Metabolism
- Analytical Methods in Pharmaceuticals
- Antibiotics Pharmacokinetics and Efficacy
- Pharmaceutical Economics and Policy
- Metabolism and Genetic Disorders
- Metabolomics and Mass Spectrometry Studies
- Ethics in Clinical Research
- Diet, Metabolism, and Disease
- Epigenetics and DNA Methylation
- Analytical Chemistry and Chromatography
University of Minnesota
2015-2024
Twin Cities Orthopedics
2020-2022
Gilead Sciences (United States)
2022
Minneapolis Institute of Arts
2020
Tufts University
2007-2016
University of Alabama at Birmingham
2007-2016
PharmacoGenetics (China)
2012
University of Córdoba
2008
Harokopio University of Athens
2008
Jean Mayer Human Nutrition Research Center on Aging
2008
Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in world. Statin‐associated musculoskeletal symptoms (SAMS) impact statin adherence ultimately can impede long‐term effectiveness of therapy. There several identified pharmacogenetic variants that disposition adverse events during SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP‐C) facilitates hepatic uptake all statins. ABCG2 an efflux (BCRP)...
Study Objective . To assess the accuracy of patient‐kept diaries relative to electronic monitoring compliance with isosorbide dinitrate prescribed 3 times/day for ischemic heart disease. Design Unblinded, prospective, three‐phase study. Methods Patients coronary artery disease were asked record time administration each dose in a pocket diary while being monitored computerized Medication‐Event Monitoring System (MEMS‐4) vial that electronically recorded date and was opened. Results...
Abstract Background: Apolipoprotein A-II (APOA2) plays an ambiguous role in lipid metabolism, obesity, and atherosclerosis. Methods: We studied the association between a functional APOA2 promoter polymorphism (−265T>C) plasma lipids (fasting postprandial), anthropometric variables, food intake 514 men 564 women who participated Genetics of Lipid Lowering Drugs Diet Network (GOLDN) study. obtained fasting postprandial (after consuming high-fat meal) measures. measured lipoprotein...
Objective— Apolipoprotein A5 ( APOA5 ) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the locus could be responsible for some observed differences in response to fenofibrate therapy. Methods and Results— We examined association between tag SNPs (−1131T>C 56C>G) TG HDL-C postprandial lipid challenge 791 men women participating GOLDN study. After 3-week drug treatment, 56G carriers displayed significant decrease P =0.006), increase =0.002) levels...
Bile acids are considered as extremely toxic at the high concentrations reached during bile duct obstruction, but each acid displays variable cytotoxic properties. This study investigates how biliary obstruction and restoration of flow interferes with urinary circulating levels 17 common acids. (conjugated unconjugated) were quantified by liquid chromatography coupled tandem mass spectrometry in serum urine samples from patients (8 men 9 women) before after stenting. Results compared...
Abstract Background Postprandial lipemia (PPL) is likely a risk factor for cardiovascular disease but these changes have not been well described and characterized in large cohort. We assessed acute the size concentration of total subclasses LDL, HDL, VLDL particles response to high-fat meal. Participants (n = 1048) from Genetics Lipid-Lowering Drugs Diet Network (GOLDN) Study who ingested meal were included this analysis. Lipids measured at 0 hr (fasting), 3.5 hr, 6 after standardized fat...
Summary Background Aspirin is associated with decreased risk of colorectal cancer (CRC), potentially by modulating the gut microbiome. Aims To evaluate effect aspirin on microbiome in a double‐blinded, randomised placebo‐controlled pilot trial. Methods Healthy volunteers aged 50‐75 received standard dose (325 mg, N = 30) or placebo (N 20) once daily for 6 weeks and provided stool samples every 3 12 weeks. Serial measurements microbial community composition bacterial abundance were derived...
Serum adiponectin levels have been positively associated with insulin sensitivity and are decreased in type 2 diabetes (T2D) obesity. Genetic environmental factors influence serum may contribute to risk of metabolic syndrome T2D. Therefore, we investigated the effect ADIPOQ single-nucleotide polymorphisms (SNPs), -11377C>G -11391G>A, on metabolic-related traits, their modulation by dietary fat white Americans. Data were collected from 1,083 subjects participating Genetics Lipid Lowering...
Fenofibrate belongs to the group of hypolipidemic fibrates that act as activators peroxisome proliferator-activated receptor-α (PPARα), which is a regulator bile acid synthesis, metabolism, and transport. The present study aimed at evaluating effects fenofibrate on circulating profile in humans. A population 200 healthy individuals comprising both genders completed 3-week intervention with fenofibrate, 17 species were measured serum samples drawn before after treatment. caused significant...
Objective Despite the evidence in support of anti-inflammatory and triglyceride-lowering effects fenofibrate, little is known about genetic determinants observed heterogeneity treatment response. This study provides first genome-wide examination fenofibrate on systemic inflammation. Methods Biomarkers inflammation were measured participants Genetics Lipid Lowering Drugs Diet Network (n=1092) before after a 3-week daily with 160 mg fenofibrate. Two inflammatory patterns [high-sensitivity...
Abstract Ginger has been associated with a decreased incidence of colorectal cancer (CRC) through reduction in inflammatory pathways and inhibition tumor growth. Recent pre-clinical models have implicated changes the gut microbiome as possible mediator ginger effect on CRC. We hypothesized that, adults previously diagnosed adenoma, supplementation would alter fecal direction consistent its CRC-inhibitory effect. Sixty-eight were randomized to take either or placebo daily for 6 weeks, 6-week...
Patients with type 2 diabetes are at increased risk of cardiovascular events, and there is an associated economic burden attached to this risk. We conducted a retrospective claims database analysis evaluate incremental costs in diabetic versus non-diabetic patients hospitalized for event. event between January 1, 2001 June 30, 2005 were identified from large US managed-care population. Diabetic by evidence the 12 months prior index hospitalization. Direct medical resource use - including...
The apolipoproteins (APOA1/C3/A4/A5) are key components in modulating lipoprotein metabolism. It is unknown whether variants at the APOA1/C3/A4/A5 gene cluster associated with lipid response to pharmacologic intervention.Plasma triglycerides (TGs) and high-density (HDL) levels were measured 861 Genetics of Lipid-Lowering Drugs Diet Network study participants who underwent a 3-week fenofibrate trial. We examined 18 common single nucleotide polymorphisms (SNPs) spanning genes investigate...
Glucuronidation, catalyzed by uridine 5′-diphospho-glucuronosyltransferase (UGT) enzymes, detoxifies cholestatic bile acids (BAs). We aimed to (i) characterize the circulating BA-glucuronide (BA-G) pool composition in humans, (ii) determine how sex and UGT polymorphisms influence this composition, (iii) analyze effects of lipid-lowering drug fenofibrate on BA-G profile 300 volunteers 5 patients. Eleven BA-Gs were determined pre- postfenofibrate samples. Men exhibited higher concentrations,...
Abstract Sixteen nuclear magnetic resonance (NMR) spectroscopy lipoprotein measurements of more than 1,000 subjects GOLDN study, at fasting and 3.5 6 h after a postprandial fat (PPL) challenge visits 2 4, before 3 weeks Fenofibrate (FF) treatment, were included in time‐independent multivariate factor analyses. Their top 1,541 unique SNPs assessed for association with NMR‐particles classical lipids. Several −log 10 p > 7.3 MAF ≥ 0.10, mostly intergenic associated NMR‐single traits near...
A recent large-scale meta-analysis of genome-wide studies has identified 95 loci, 59 them novel, as statistically significant predictors blood lipid traits; we tested whether the same loci explain observed heterogeneity in response to lipid-lowering therapy with fenofibrate. Using data from Genetics Lipid Lowering Drugs and Diet Network (GOLDN, n = 861) fit linear mixed models genetic markers high-density lipoprotein (HDL) cholesterol, low-density (LDL) total triglyceride concentrations...